Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Atsushi Mitsuhashi"'
Autor:
Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Na Thi Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara, Yasuhiko Nishioka
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 369-378 (2024)
Abstract Background Immune checkpoint inhibitors (ICIs) are a revolutionary paradigm in the treatment of thoracic malignancies and chemoimmunotherapy is a current standard care in this field. Chemotherapeutic agents are known to induce not only direc
Externí odkaz:
https://doaj.org/article/3b039c22a72a49ee860a78baa3226a06
Autor:
Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Sato, Hisatsugu Goto, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, Shinohara Tsutomu, Yasuhiko Nishioka
Publikováno v:
Thoracic Cancer, Vol 14, Iss 32, Pp 3232-3239 (2023)
Abstract Background Although the incidence of lung cancer in elderly individuals has been increasing in recent years, the number of clinical trials designed specifically for elderly patients with advanced non‐small cell lung cancer (NSCLC) is still
Externí odkaz:
https://doaj.org/article/0bcc20ae3023490cbf17233bd45b1ae2
Autor:
Kenya Miyamoto, Hirokazu Ogino, Takumi Kakimoto, Yugo Matsumura, Keiko Haji, Atsushi Mitsuhashi, Yutaka Morita, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Yoshimi Bando, Hiroshi Nokihara, Yasuhiko Nishioka
Publikováno v:
Respiratory Medicine Case Reports, Vol 51, Iss , Pp 102076- (2024)
Histological transformation to small-cell lung cancer (SCLC) is a well-known mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), and almost all patients receive EGFR-TKIs at the time of transfo
Externí odkaz:
https://doaj.org/article/d8dbc032b64a4fa6a301539b481e6524
Autor:
Kenji Otsuka, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino, Yasuhiko Nishioka
Publikováno v:
Thoracic Cancer, Vol 13, Iss 21, Pp 2978-2984 (2022)
Abstract Background Treatment of non‐small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) is limited because of the risk of its acute exacerbation (AE). Furthermore, the efficacy and safety of second‐line chemotherapy for
Externí odkaz:
https://doaj.org/article/fb80371d51434a9890dcc0d7ec5d0723
Autor:
Hiroshi Nokihara, Hirokazu Ogino, Atsushi Mitsuhashi, Kensuke Kondo, Ei Ogawa, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Kenji Otsuka, Yasuhiko Nishioka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Osimertinib is a standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Although malignant pleural effusion (PE) is a common clinical problem in N
Externí odkaz:
https://doaj.org/article/fd70bfd9fd224ee1bb2c84a89f08739b
Autor:
Yutaka Morita, Atsuro Saijo, Hiroshi Nokihara, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yoshimi Bando, Yasuhiko Nishioka
Publikováno v:
Thoracic Cancer, Vol 13, Iss 7, Pp 1079-1082 (2022)
Abstract Radiation therapy (RT) activates the antigen presentation of dendritic cells and priming of cancer‐specific cytotoxic CD8+ T cells, occasionally resulting in a systemic immune response to the tumor outside of the treatment field. The pheno
Externí odkaz:
https://doaj.org/article/ef5a1d1a38404387a0a38f02432102f3
Autor:
Masahiro Sako, Hiroshi Nokihara, Kensuke Kondo, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Akane Abe, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka, Hisanori Uehara, Yasuhiko Nishioka
Publikováno v:
Thoracic Cancer, Vol 13, Iss 1, Pp 129-132 (2022)
Abstract Pulmonary pleomorphic carcinoma is often refractory to chemotherapy and follows an aggressive clinical course. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, and a few cases with pleomorphic ca
Externí odkaz:
https://doaj.org/article/c87d33cc23b04e469beeecb0208f2c24
Autor:
Hiroki Takahashi, Hirokazu Ogino, Hiroki Bando, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Sato, Masaki Hanibuchi, Yasuhiko Nishioka
Publikováno v:
Respiratory Medicine Case Reports, Vol 45, Iss , Pp 101893- (2023)
A non-smoker woman with advanced lung adenocarcinoma was referred to us. The Oncomine Dx target test (ODxTT), a next-generation sequencing (NGS)-based hot spots panel test, did not detect any driver mutations, so we treated her with chemo-immunothera
Externí odkaz:
https://doaj.org/article/73c471de01134955b36aa64892c73abc
Autor:
Seiya Ichihara, Hirokazu Ogino, Hiroto Yoneda, Keiko Haji, Kozo Kagawa, Kojin Murakami, Masato Mima, Yu Aoi, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Seidai Sato, Hiroshi Nokihara, Yasuhiko Nishioka
Publikováno v:
Respiratory Medicine Case Reports, Vol 41, Iss , Pp 101797- (2023)
A man with non-small-cell lung cancer who was negative for anti-nuclear antibodies was admitted for dyspnea after immune checkpoint inhibitor (ICI) administration. Computed tomography (CT) showed complexed radiologic features, including subpleural an
Externí odkaz:
https://doaj.org/article/7a6cbd5292674aa692a63a3ed843bb40
Autor:
Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka, Yasuhiko Nishioka
Publikováno v:
BMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-6 (2021)
Abstract Background Nivolumab is used for the treatment of malignant pleural mesothelioma (MPM). However, immune-related adverse events (irAEs) occur in patients treated with nivolumab. Several studies have reported the correlation between irAEs and
Externí odkaz:
https://doaj.org/article/283e2c804e1e4caca2a024bc86d5df46